Efeito da catuama® na sintomatologia da síndrome da ardência bucal: ensaio clínico, randomizado, duplo-cego, placebo-controlado

• Ano de defesa: 2011
• Autor(a) principal: Spanemberg, Juliana Cassol
• Orientador(a): Salum, Fernanda Gonçalves
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Pontifícia Universidade Católica do Rio Grande do Sul; Porto Alegre
• Palavras-chave em Português: ODONTOLOGIA; ESTOMATOLOGIA; TERAPÊUTICA; FITOTERAPIA; SÍNDROME DA ARDÊNCIA BUCAL
• Link de acesso: http://hdl.handle.net/10923/389

Burning mouth syndrome (BMS) is a disease of unknown etiopathogenesis, characterized by a burning sensation on the oral mucosa, which appears clinically normal. Antidepressants, benzodiazepines and antipsychotics are the options most taken in the treatment of BMS. Studies have demonstrated that the herbal product Catuama® , composed of four extracts of medicinal plants (Paullinia cupana, Trichilia catigua, Zingiber officinalis and Ptychopetalum olacoides), has vasorelaxant, antinociceptive and antidepressant actions. This randomized, double-blind, placebo-controlled clinical study aimed at evaluating the effect of the systemic use of Catuama® on the symptoms of BMS throught faces scale (FS) and visual numeric scale (VNS). Seventy-two patients with a diagnosis of BMS were randomly distributed into test (n=38) and control (n=34) groups. The study included patients with a minimal age of 40 years old who reported symptoms of burning or pain in the oral mucosa, with at least six months, and who presented with a clinically normal mucosa. Individuals who were taking antidepressants, anxiolytics or anticonvulsants drugs; patients who showed hyposalivation, alterations in hemogram, serum levels of glucose, iron, folic acid and vitamin B12 were excluded. Patients were instructed to take two capsules each day for eight weeks and they were reassessed after 4, 8 and 12 weeks. Sixty subjects completed the study. Although both groups demonstrated a reduction in symptoms, the improvement seen in the test group was significantly higher than in the control group after 4 (FS, p=0. 010) and 8 (VNS, p=0. 03; FS, p=0<0. 001) weeks of treatment. Four weeks after the end of treatment, the patients maintained a mean percentage of symptom reduction at 51. 3%, while in the control group the reduction in symptoms was 18. 8% (VNS, p=0. 001).Based on the protocol employed, the systemic administration of Catuama® reduces the symptoms of the disease and can be a novel therapeutic strategy, with less side effects, when compared to drugs commonly utilized in the treatment of BMS.